Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II reduced-toxicity submyeloablative conditioning with busulfan before allogeneic hematopoietic stem cell transplantation for malignant hematologic diseases
2008-006175-75Phase 2Active
- Sponsor
- CHU de Nantes
- Start
- Oct 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan in hematopoietic malignancies, sponsored by CHU de Nantes. Primary endpoint: Overall mortality at 12 months after allogeneic transplantation. Started Oct 2008; status: active.
02
Drugs
busulfan
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on 2008-006175-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006175-75.